These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38627969)

  • 1. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.
    Skeate JG; Pomeroy EJ; Slipek NJ; Jones BJ; Wick BJ; Chang JW; Lahr WS; Stelljes EM; Patrinostro X; Barnes B; Zarecki T; Krueger JB; Bridge JE; Robbins GM; McCormick MD; Leerar JR; Wenzel KT; Hornberger KM; Walker K; Smedley D; Largaespada DA; Otto N; Webber BR; Moriarity BS
    Mol Ther; 2024 Jun; 32(6):1817-1834. PubMed ID: 38627969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
    Bexte T; Botezatu L; Miskey C; Gierschek F; Moter A; Wendel P; Reindl LM; Campe J; Villena-Ossa JF; Gebel V; Stein K; Cathomen T; Cremer A; Wels WS; Hudecek M; Ivics Z; Ullrich E
    Mol Ther; 2024 Jul; 32(7):2357-2372. PubMed ID: 38751112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
    Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
    Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System.
    Bauser M; Einsele H; Löffler J; Hudecek M; Seif M
    J Vis Exp; 2024 Oct; (212):. PubMed ID: 39431788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression.
    Ma L; Zhang K; Xu J; Wang J; Jiang T; Du X; Zhang J; Huang J; Ren F; Liu D; Xue W; Kan D; Yao M; Liang Y; Jason-Sun H
    Mol Ther; 2024 Aug; 32(8):2728-2740. PubMed ID: 38879754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.
    Prommersberger S; Monjezi R; Botezatu L; Miskey C; Amberger M; Mestermann K; Hudecek M; Ivics Z
    Methods Mol Biol; 2022; 2521():41-66. PubMed ID: 35732992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Production of Lentiviral Vectors for CAR-T Cell.
    Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells.
    Du Z; Zhao T; Chen X; Zha S; Wang S
    Methods Mol Biol; 2024; 2748():279-288. PubMed ID: 38070120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.